Back to Journals » Neuropsychiatric Disease and Treatment » Volume 5

Update on ropinirole in the treatment of Parkinson’s disease

Authors Shill HA, Stacy M

Published 21 December 2008 Volume 2009:5 Pages 33—36

DOI https://doi.org/10.2147/NDT.S3237

Review by Single-blind

Peer reviewer comments 3


Holly A Shill, Mark Stacy

Sun Health Research Institute, Sun City, AZ, USA; Duke University and Medical Center, Durham, NC, USA

Abstract: Ropinirole is a dopamine agonist, approved for use to treat symptoms of early and advanced Parkinson’s disease, is now available in a 24-hour formulation in addition to the immediate release version. This review discusses the mode of action of ropinirole and compares the pharmacokinetics of both formulations. Pivotal studies leading to the approval of both preparations are reviewed in terms of efficacy, dose range and side effects. Patient factors such as compliance are discussed in terms of the place for ropinirole in the armamentarium of Parkinson’s disease therapies.

Keywords: ropinirole extended release, ropinirole immediate release Parkinson’s disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]